Table 3.

Protection against SHIV mucosal challenge following topical administration of HIV-MAbs

Reference	MAb(s)	MAb Dosage	Route	SHIV Challenge	Protection	Notes
Veazey [48]	b12	5 mg	Vaginal	Vaginal, sHDa SHIV162P4	9/12	First topical mAb efficacy study.
Burton [18]	b12 b6 F240 b12 b6 F240	5 mg ″ ″ 5 mg ″ ″	Vaginal ″ ″ Vaginal ″ ″	Vaginal, sHD SHIV162P4 ″ ″ Vaginal, sHD SHIV162P3 ″ ″	5/5 0/5 2/5 1/4 1/4 1/4	Strong neutralizing mAb (b12) more protective than weakly neutralizing mAbs (b6, F240). MAbs less effective against Tier 2 virus (SHIV162P3)
Watkins [49]	HGN 194 IgG1 HGN 194 dIgA1 HGN 194 dIgA2	1.25 mg ″ ″	Rectal ″ ″	Rectal, sHD SHIV1157ipEL-p ″ ″	2/6 5/6 1/6	dIgA1 was more protective than IgG1 or dIgA2 mAbs.
Moog [19]	2G12 + 2F5 + 4E10 246-D + 4B3	20 mg @ mAb 30 mg @ mAb	Vaginal Vaginal	Vaginal, sHD SHIV162P3 ″	10/15 0/15	Neutralizing mAbs (2G12, 2F5, 4E10) were more effective than non-neutralizing mAbs (246-D and 4B3). Tier 2 SHIV was used.
Sholukh [47]	HGN 194 IgG1 HGN 194 IgG1 + dIgA2	1.45 mg/kg 1.45 mg/kg + 1.25 mg	IV IV + Rectal	Rectal, sHD SHIV1157ipEL-p ″	0/6 6/6	Rectal administration of dIgA2 mAb enhanced protection against rectal SHIV challenge.
Zhao [50]	4E10-Nb ″ ″ VRC01-N ″ ″	1.25 mg 5 mg 20 mg 1.25 mg 5 mg 20 mg	Vaginal ″ ″ Vaginal ″ ″	Vaginal, rLDc SHIV162P3 ″ ″ Vaginal, rLD SHIV162P3 ″ ″	0/5 0/5 0/5 3/5 4/5 5/5	First study to use “plantibodies”, repeated low dose challenge with Tier 2 SHIV.
Astronomo [17]	CH31 IgG1 CH31 m-IgA2 CH31 d-IgA2 CH31 s-IgA2	5 mg ″ ″ ″	Rectal ″ ″ ″	Rectal, sHD SHIVSF162P3 ″ ″ ″	6/6 3/6 5/6 4/6	IgG1 was more protective than IgA2 forms.

^asHD: Single high dose SHIV challenge;

^b-N, mab made in Nicotiana benthamiana;

^crLD: Repeated low dose SHIV challenge